Amgen is running a number of studies of its obesity drug, MariTide.

--Amgen today announced new data from a real-world study of nearly half of a million postmenopausal women with osteoporosis in the U.S. medicare program showing Prolia ® injection reduced fracture ...

The FDA has added a serious warning to the prescribing information for Amgen Inc’s (NASDAQ:AMGN) drug Prolia (denosumab), emphasizing an increased risk of severely low calcium levels in specific ...

Update 11:25am on April 30: Adds Amgen, Sandoz comment. A preliminary injunction hearing in an Amgen (NASDAQ:AMGN) patent lawsuit against Sandoz (OTCQX:SDZNY) over potential generic entry of its ...

(Corrects paragraph 5 in February 5 story to say 2025 Prolia sales were $4.4 billion, not $1.05 billion) Feb 5 (Reuters) - ...

A blockbuster Amgen antibody that treats bone conditions is set to face its first biosimilar competition. The FDA on Tuesday approved two Sandoz drugs as interchangeable with and approved for all uses ...

Aug 13 (Reuters) - Amgen (AMGN.O), opens new tab has sued Samsung's biologics unit (207940.KS), opens new tab in New Jersey federal court over its proposed biosimilar versions of Amgen's blockbuster ...

Biocon Biologics agreed to a settlement-and-license agreement with Amgen that will permit it to market drugs in the United States that are biosimilars to Amgen's Prolia and Xgeva. Both medications use ...

NEW YORK (Reuters) - The U.S. Food and Drug Administration approved on Tuesday the sale of Amgen Inc's osteoporosis drug Prolia to help prevent fractures in post-menopausal women just days after the ...